alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with oxazoles in 1 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (oxazoles) | Trials (oxazoles) | Recent Studies (post-2010) (oxazoles) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 9,281 | 366 | 2,561 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreas, J; Benkert, O; Eissner, D; Gründer, G; Heydari, N; Müller, MJ; Nickel, O; Schlegel, S; Schlösser, R; Wetzel, H | 1 |
1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and oxazoles
| Article | Year |
|---|---|
Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzamides; Blood-Brain Barrier; Corpus Striatum; Female; Humans; Male; Middle Aged; Oxazoles; Piperidines; Pyrimidines; Pyrrolidines; Receptors, Dopamine D2; Receptors, sigma; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1999 |